NCT04004442 - Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

April 7, 2022

Study Completion Date

September 30, 2025

Conditions

Urothelial Carcinoma

Interventions

DRUG

Avelumab

Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)

DRUG

AVB-S6-500

AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)

Trial Locations (1)

73104

Stephenson Cancer Center, Oklahoma City